| Full Name | Akash Parashar |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 85 High St, Buffalo, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538365432 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 002871 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Of Buffalo | Buffalo, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Hospital Of Buffalo | 8729991666 | 165 |
News Archive
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.
Some speciality publications are covering the dispute over possible impact on dentists, doctors and other medical professionals.
Here's the dilemma: The only way for the health-care industry to move toward accountable care is to further accelerate a process of consolidation that has already reduced competition and increased market power. … In such a market, government may be required to step in with more direct regulation and competition management than traditional antitrust rules now provide (Steven Pearlstein, 11/23).
› Verified 6 days ago
| Entity Name | Kaleida Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366473183 PECOS PAC ID: 7810805280 Enrollment ID: O20031105000212 |
News Archive
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.
Some speciality publications are covering the dispute over possible impact on dentists, doctors and other medical professionals.
Here's the dilemma: The only way for the health-care industry to move toward accountable care is to further accelerate a process of consolidation that has already reduced competition and increased market power. … In such a market, government may be required to step in with more direct regulation and competition management than traditional antitrust rules now provide (Steven Pearlstein, 11/23).
› Verified 6 days ago
| Entity Name | Buffalo Medical Group, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881659506 PECOS PAC ID: 7012820301 Enrollment ID: O20031112000213 |
News Archive
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.
Some speciality publications are covering the dispute over possible impact on dentists, doctors and other medical professionals.
Here's the dilemma: The only way for the health-care industry to move toward accountable care is to further accelerate a process of consolidation that has already reduced competition and increased market power. … In such a market, government may be required to step in with more direct regulation and competition management than traditional antitrust rules now provide (Steven Pearlstein, 11/23).
› Verified 6 days ago
| Entity Name | Sisters Of Charity Hospital Of Buffalo New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790727543 PECOS PAC ID: 6204749153 Enrollment ID: O20031126000557 |
News Archive
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.
Some speciality publications are covering the dispute over possible impact on dentists, doctors and other medical professionals.
Here's the dilemma: The only way for the health-care industry to move toward accountable care is to further accelerate a process of consolidation that has already reduced competition and increased market power. … In such a market, government may be required to step in with more direct regulation and competition management than traditional antitrust rules now provide (Steven Pearlstein, 11/23).
› Verified 6 days ago
| Entity Name | Mercy Hospital Of Buffalo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164464921 PECOS PAC ID: 8729991666 Enrollment ID: O20040702001253 |
News Archive
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.
Some speciality publications are covering the dispute over possible impact on dentists, doctors and other medical professionals.
Here's the dilemma: The only way for the health-care industry to move toward accountable care is to further accelerate a process of consolidation that has already reduced competition and increased market power. … In such a market, government may be required to step in with more direct regulation and competition management than traditional antitrust rules now provide (Steven Pearlstein, 11/23).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Akash Parashar, 425 Essjay Rd Ste 170, Williamsville, NY 14221-8235 Ph: (716) 630-1219 | Akash Parashar, 85 High St, Buffalo, NY 14203-1149 Ph: (716) 630-1000 |
News Archive
Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).
University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.
Some speciality publications are covering the dispute over possible impact on dentists, doctors and other medical professionals.
Here's the dilemma: The only way for the health-care industry to move toward accountable care is to further accelerate a process of consolidation that has already reduced competition and increased market power. … In such a market, government may be required to step in with more direct regulation and competition management than traditional antitrust rules now provide (Steven Pearlstein, 11/23).
› Verified 6 days ago
Nirmit Dilipkumar Kothari, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 462 Grider St, Room 786, Buffalo, NY 14215 Phone: 716-961-6995 Fax: 716-898-5276 | |
Dr. Fatemeh Moslehi, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 462 Grider St, Buffalo, NY 14215 Phone: 716-898-4226 | |
Dr. Romel Adupe Bertulfo, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 565 Abbott Rd, Rm. 8-632, Buffalo, NY 14220 Phone: 716-828-2434 Fax: 726-828-3417 | |
David Lee Pierce, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 462 Grider St, Buffalo, NY 14215 Phone: 716-898-3000 | |
Mamoon Bokhari, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Elm And Carlton Streets, Buffalo, NY 14263 Phone: 716-845-2300 Fax: 716-845-1110 | |
Peter Ewing, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 100 High St, Buffalo, NY 14203 Phone: 716-859-2259 | |
Erlin J. Marte, DO, MD, MS Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 85 High St, Buffalo, NY 14203 Phone: 716-857-8801 Fax: 716-817-1781 |